Annual report pursuant to Section 13 and 15(d)

Common Stock

v3.3.1.900
Common Stock
12 Months Ended
Dec. 31, 2015
Equity [Abstract]  
Common Stock

10. COMMON STOCK

[a] Authorized

75,000,000 authorized common voting share, par value of $0.001, and 5,000,000 preferred shares, par value of $0.001.

[b] Issued and outstanding shares

At-The-Market Issuance Sales Agreement

In June 2013, we entered into an At-the-Market Issuance Sales Agreement, or Sales Agreement, with MLV & Co. LLC, or MLV, under which we may offer and sell shares of our common stock having aggregate sales proceeds of up to $25 million from time to time through MLV as our sales agent. Sales of our common stock through MLV, if any, will be made by any method permitted that is deemed an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, including by means of ordinary brokers’ transactions on The NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and MLV. MLV will use commercially reasonable efforts to sell our common stock from time to time, based upon instructions from us (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay MLV a commission of up to 3.0% of the gross sales proceeds of any shares of common stock sold through MLV under the Sales Agreement. We are not obligated to make any sales of common stock under the Sales Agreement. The offering of our shares of common stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms.

On April 27, 2015, we and MLV terminated the Sales Agreement. We were not subject to any termination penalties related to termination of the Sales Agreement. Under the Sales Agreement, we offered and sold 809,214 shares of our common stock with MLV & Co. LLC. These sales resulted in gross proceeds to us of approximately $3.0 million and offering expenses of $0.1 million.

July 2014 Registered Offering

On July 2, 2014, we completed an underwritten registered offering pursuant to which we sold 5,559,866 Series A units at a price per unit of $3.48 and 1,340,538 Series B units at a price per unit of $3.47.

Each Series A unit consisted of one share of common stock and a Series A warrant to purchase up to one-half of one share of common stock at an initial exercise price of $4.00 per share. Each Series A warrant is exercisable at any time on or after the date of issuance until the fifth anniversary of the issuance of the Series A warrants.

Each Series B unit consisted of a Pre-Funded Series B warrant to purchase up to one share of common stock at an initial exercise price of $0.01 per share and a Series B warrant to purchase up to one-half of one share of common stock at an initial exercise price of $4.00 per share. Each Pre-Funded Series B warrant and Series B warrant is exercisable at any time on or after the date of issuance until the fifth anniversary of the issuance of the Pre-Funded Series B warrants and Series B warrants, respectively.

We received net proceeds of approximately $22.4 million, after deducting underwriting discounts and commissions and offering expenses. Gross proceeds of $24.0 million and underwriting discounts and commissions and offering expenses of $1.6 million were allocated as follows:

 

 

 

 

 

 

 

Series B

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pre-funded

 

 

Series A

 

 

Series B

 

 

 

 

 

 

 

Common

 

 

Common

 

 

Common

 

 

 

Common

 

 

Stock

 

 

Stock

 

 

Stock

 

 

 

Stock

 

 

Warrants

 

 

Warrants

 

 

Warrants

 

Units Issued

 

 

5,559,866

 

 

 

1,340,538

 

 

 

2,779,933

 

 

 

670,269

 

Gross Proceeds (in thousands)

 

$

14,084

 

 

$

3,387

 

 

$

5,261

 

 

$

1,268

 

Underwriting discount and offering expense (in thousands)

 

$

885

 

 

$

213

 

 

$

428

 

 

$

103

 

 

The Series A and Series B common stock warrants are classified as liabilities. The underwriting discount and offering expenses allocated to the Series A and Series B common stock warrants have been expensed in the Consolidated Statement of Loss.

The common stock and Series B prefunded common stock warrants are classified as equity. The underwriting discount and offering expenses allocated to the common stock and Series B prefunded common stock warrants have been charged against the allocated gross proceeds.

Purchase Agreement and Financing with Lincoln Park Capital

On April 30, 2015, we and Lincoln Park Capital Fund, LLC, or LPC, entered into a share and unit purchase agreement, or Purchase Agreement, pursuant to which we have the right to sell to LPC up to $18.0 million in shares of our common stock, par value $0.001 per share, subject to certain limitations and conditions set forth in the Purchase Agreement.  

Pursuant to the Purchase Agreement, LPC initially purchased 956,938 Series A-1 Units at a purchase price of $2.09 per unit, with each Series A-1 Unit consisting of (a) one share of Common Stock and (b) one warrant to purchase one-quarter of a share of Common Stock at an exercise price of $2.40 per share, or Series A-1 Warrant.  Each Series A-1 Warrant is exercisable six months following the issuance date until the date that is five years and six months after the issuance date and is subject to customary adjustments.  The Series A-1 Warrants were issued only as part of the Series A-1 Units in the initial purchase of $2.0 million and no warrants were issued in connection with any other purchases of common stock under the Purchase Agreement.

 

After the initial purchase, as often as every business day over the 24-month term of the Purchase Agreement, and up to an aggregate amount of an additional $16.0 million (subject to certain limitations) of shares of common stock, we had the right, from time to time, in our sole discretion and subject to certain conditions to direct LPC to purchase up to 125,000 shares of common stock with such amounts increasing as the closing sale price of our common stock as reported on The NASDAQ Capital Market increased. The purchase price of shares of common stock pursuant to the Purchase Agreement was based on prevailing market prices of common stock at the time of sales without any fixed discount, and we controlled the timing and amount of common stock sold to LPC. In addition, we had the right to direct LPC to purchase additional amounts as accelerated purchases if on the date of a regular purchase the closing sale price of the common stock is not below $1.50 per share. As consideration for entering into the Purchase Agreement, we issued to LPC 126,582 shares of common stock; no cash proceeds were received from the issuance of these shares.

From April 30, 2015 through August 13, 2015, we offered and sold 6,814,980 shares of our common stock pursuant to our Purchase Agreement with LPC. These sales resulted in gross proceeds to us of approximately $18.0 million and offering expenses of $0.4 million. As of August 13, 2015, no further amounts remained available for sale under this offering program

Stock Option Exercises

During the year ended December 31, 2015, we issued 5,359 and 269,401 shares of common stock to satisfy stock option exercises and restricted stock unit settlements, respectively, compared with the issuance of 10,000 and 203,148 shares of common to satisfy stock option exercises and restricted stock unit settlements, respectively, for the years ended December 31, 2014. For the year ended December 31, 2013, we issued 3,475 and 47,495 shares of common stock to satisfy stock option exercises and restricted stock unit settlements, respectively.  

[c] Stock options

As at December 31, 2015 we had reserved, pursuant to our 2010 Performance Incentive Plan, 3,876,151 common shares for issuance upon exercise of stock options and settlement of restricted stock units by employees, directors, officers and consultants of ours, of which 1,479,221 are reserved for options currently outstanding, 640,759 are reserved for restricted stock units currently outstanding and 1,756,171 are available for future equity award grants under our 2010 Performance Incentive Plan. As of December 31, 2014 2,906,777 shares were available for equity award grants under our 2010 Performance Incentive Plan.

2010 Performance Incentive Plan

At our 2013 Annual Meeting of Stockholders held on May 24, 2013, our stockholders approved an amendment to our 2010 Performance Incentive Plan. As a result of this amendment, the 2010 Plan was further amended to provide for an increase in the total shares of common stock available for issuance under the 2010 Plan from 1,050,000 to 2,050,000. At our 2014 Annual Meeting of Stockholders held on May 29, 2014, our stockholders approved an amendment to our 2010 Performance Incentive Plan. As a result of this amendment, the 2010 Plan was amended to provide for an increase in the total shares of common stock available for issuance under the 2010 Plan from 2,050,000 to 2,800,000. At our 2015 Annual Meeting of Stockholders held on May 21, 2015, our stockholders approved an amendment to our 2010 Performance Incentive Plan. As a result of this amendment, the 2010 Plan was amended to provide for an increase in the total shares of common stock available for issuance under the 2010 Plan from 2,800,000 to 4,300,000.

Under the plan, we may grant options to purchase common shares or restricted stock units to our employees, directors, officers and consultants. The exercise price of the options is determined by our board of directors but will be at least equal to the fair value of the common shares at the grant date. The options vest in accordance with terms as determined by our board of directors, typically over three to four years for options issued to employees and consultants, and over one to three years for members of our board of directors. The expiry date for each option is set by our board of directors with a maximum expiry date of ten years from the date of grant.

Options remain outstanding under a number of share option plans that had been approved by shareholders prior to the approval of the 2010 Performance Incentive Plan: (a) the 2000 Stock Incentive Plan (2000 Plan), (b) the 2007 Performance Incentive Plan (2007 Plan) and (c) the OncoGenex Technologies Inc. Stock Option Plan (OncoGenex Technologies Plan).

ASC 718 Compensation – Stock Compensation

We recognize expense related to the fair value of our stock-based compensation awards using the provisions of ASC 718. We use the Black-Scholes option pricing model as the most appropriate fair value method for our stock options and recognize compensation expense for stock options on a straight-line basis over the requisite service period. In valuing our stock options using the Black-Scholes option pricing model, we make assumptions about risk-free interest rates, dividend yields, volatility and weighted average expected lives, including estimated forfeiture rates of the options.

The expected life was calculated based on the simplified method as permitted by the SEC’s Staff Accounting Bulletin 110, Share-Based Payment. We consider the use of the simplified method appropriate because we believe our historical stock option exercise activity may not be indicative of future stock option exercise activity because of the AFFINITY clinical data results we expect to receive in the third quarter of 2016, the structural changes to our business that may result and the potential impact of that data on our business operations and future stock option exercise activity. The expected volatility of options granted was calculated based on the historical volatility of the shares of our common stock. The risk-free interest rate is based on a U.S. Treasury instrument whose term is consistent with the expected life of the stock options. In addition to the assumptions above, as required under ASC 718, management made an estimate of expected forfeitures and is recognizing compensation costs only for those equity awards expected to vest. Forfeiture rates are estimated using historical actual forfeiture rates. These rates are adjusted on a quarterly basis and any change in compensation expense is recognized in the period of the change. We have never paid or declared cash dividends on our common stock and do not expect to pay cash dividends in the foreseeable future.

The estimated fair value of stock options granted in the respective periods was determined using the Black-Scholes option pricing model using the following weighted average assumptions:

 

 

 

2015

 

 

2014

 

 

2013

 

Risk-free interest rates

 

 

1.76

%

 

 

1.83

%

 

 

1.25

%

Expected dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

Expected life

 

5.8 years

 

 

5.9 years

 

 

5.8 years

 

Expected volatility

 

 

63

%

 

 

82

%

 

 

86

%

 

The weighted average fair value of stock options granted during the year ended December 31, 2015, 2014 and 2013 was $1.10, $6.52 and $8.07 per share, respectively.

The results for the periods set forth below included stock-based compensation expense in the following expense categories of the consolidated statements of loss (in thousands):

 

 

 

Years ended

 

 

 

December 31,

 

 

 

2015

 

 

2014

 

 

2013

 

Research and development

 

$

1,111

 

 

$

1,893

 

 

$

1,296

 

General and administrative

 

 

1,217

 

 

 

1,967

 

 

 

1,538

 

Total stock-based compensation

 

$

2,328

 

 

$

3,860

 

 

$

2,834

 

 

Options vest in accordance with terms as determined by our board of directors, typically over three or four years for employee and consultant grants and over one or three years for board of director option grants. The expiry date for each option is set by our board of directors with, which is typically seven to ten years. The exercise price of the options is determined by our board of directors but is at least equal to the fair value of the share at the grant date.

Stock option transactions and the number of stock options outstanding are summarized below:

 

 

 

Number of

 

 

Weighted

 

 

 

Optioned

 

 

Average

 

 

 

Common

 

 

Exercise

 

 

 

Shares

 

 

Price

 

Balance, January 1, 2013

 

 

805,281

 

 

$

11.34

 

Granted

 

 

239,282

 

 

 

11.32

 

Expired

 

 

(3,061

)

 

 

4.11

 

Exercised

 

 

(3,475

)

 

 

3.00

 

Forfeited

 

 

(30,536

)

 

 

13.87

 

Balance, December 31, 2013

 

 

1,007,491

 

 

$

11.39

 

Granted

 

 

382,097

 

 

 

8.97

 

Expired

 

 

(12,169

)

 

 

18.93

 

Exercised

 

 

(10,000

)

 

 

3.00

 

Forfeited

 

 

(84,000

)

 

 

12.14

 

Balance, December 31, 2014

 

 

1,283,419

 

 

$

10.55

 

Granted

 

 

502,047

 

 

 

1.91

 

Expired

 

 

(247,766

)

 

 

2.96

 

Exercised

 

 

(5,359

)

 

 

2.69

 

Forfeited

 

 

(53,120

)

 

 

14.37

 

Balance, December 31, 2015

 

 

1,479,221

 

 

$

8.78

 

 

The following table summarizes information about stock options outstanding at December 31, 2015 regarding the number of ordinary shares issuable upon: (1) outstanding options and (2) vested options.

(1) Number of common shares issuable upon exercise of outstanding options:

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

Remaining

 

 

 

 

 

 

 

Weighted-

 

 

Contractual

 

 

 

 

 

 

 

Average

 

 

Life

 

Exercise Prices

 

Number of Options

 

 

Exercise Price

 

 

(in years)

 

$1.16 - $1.54

 

 

8,750

 

 

$

1.17

 

 

 

9.93

 

$1.55 - $1.88

 

 

424,797

 

 

 

1.86

 

 

 

9.38

 

$1.89 - $3.04

 

 

115,500

 

 

 

2.35

 

 

 

9.24

 

$3.05 - $11.17

 

 

143,879

 

 

 

5.89

 

 

 

7.09

 

$11.18 - $11.84

 

 

218,147

 

 

 

11.78

 

 

 

8.14

 

$11.85 - $11.99

 

 

154,251

 

 

 

11.95

 

 

 

7.14

 

$12.00 - $13.06

 

 

136,325

 

 

 

12.87

 

 

 

6.26

 

$13.07 - $15.74

 

 

37,676

 

 

 

14.33

 

 

 

5.35

 

$15.75 - $16.40

 

 

110,250

 

 

 

15.97

 

 

 

4.96

 

$16.41 - $22.28

 

 

129,646

 

 

 

20.06

 

 

 

4.23

 

Total

 

 

1,479,221

 

 

$

8.78

 

 

 

7.56

 

 

(2) Number common shares issuable upon exercise of vested options:

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

Remaining

 

 

 

 

 

 

 

Weighted-

 

 

Contractual

 

 

 

 

 

 

 

Average

 

 

Life

 

Exercise Prices

 

Number of Options

 

 

Exercise Price

 

 

(in years)

 

$1.16 - $1.54

 

 

547

 

 

$

1.17

 

 

 

9.93

 

$1.55 - $1.88

 

 

96,695

 

 

 

1.86

 

 

 

9.38

 

$1.89 - $3.04

 

 

19,042

 

 

 

2.44

 

 

 

9.05

 

$3.05 - $11.17

 

 

99,764

 

 

 

6.58

 

 

 

6.50

 

$11.18 - $11.84

 

 

107,491

 

 

 

11.78

 

 

 

8.07

 

$11.85 - $11.99

 

 

113,949

 

 

 

11.95

 

 

 

7.12

 

$12.00 - $13.06

 

 

134,044

 

 

 

12.87

 

 

 

6.26

 

$13.07 - $15.74

 

 

35,284

 

 

 

14.39

 

 

 

5.25

 

$15.75 - $16.40

 

 

110,250

 

 

 

15.97

 

 

 

4.96

 

$16.41 - $22.28

 

 

129,646

 

 

 

20.06

 

 

 

4.23

 

Total

 

 

846,712

 

 

$

11.93

 

 

 

6.53

 

 

As at December 31, 2015, the total unrecognized compensation expense related to stock options granted was $1.8 million, which is expected to be recognized into expense over a period of approximately 2.1 years.

The estimated grant date fair value of stock options vested during the years ended December 31, 2015, 2014 and 2013 was $1.3 million, $1.9 million and $1.8 million, respectively.

The aggregate intrinsic value of options exercised was calculated as the difference between the exercise price of the stock options and the fair value of the underlying common stock as of the date of exercise. The aggregate intrinsic value of options exercised for the years ended December 31, 2015, 2014 and 2013 was $2,787, $51,100 and $34,000, respectively. At December 31, 2015, the aggregate intrinsic value of the outstanding options was $350 and the aggregate intrinsic value of the exercisable options was zero.

[d] Restricted Stock Unit Awards

We grant restricted stock unit awards that generally vest and are expensed over a four year period. We also grant restricted stock unit awards that vest in conjunction with certain performance conditions to certain executive officers and key employees. At each reporting date, we are required to evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision. For the years ended December 31, 2015, 2014 and 2013, $1.1 million, $2.2 million and $1.1 million, respectively, of stock based compensation expense was recognized related to these awards.

The following table summarizes our restricted stock unit award activity during the years ended December 31, 2015, 2014 and 2013:

 

 

 

 

 

 

 

Weighted

 

 

 

Number

 

 

Average

 

 

 

of

 

 

Grant Date

 

 

 

Shares

 

 

Fair Value

 

Balance, January 1, 2013

 

 

172,085

 

 

$

13.01

 

Granted

 

 

255,895

 

 

 

11.64

 

Vested

 

 

(50,773

)

 

 

12.95

 

Forfeited or expired

 

 

(20,618

)

 

 

12.51

 

Balance, December 31, 2013

 

 

356,589

 

 

$

12.06

 

Granted

 

 

814,800

 

 

 

6.48

 

Vested

 

 

(199,887

)

 

 

7.00

 

Forfeited or expired

 

 

(291,301

)

 

 

10.93

 

Balance, December 31, 2014

 

 

680,201

 

 

$

7.34

 

Granted

 

 

249,775

 

 

 

1.92

 

Vested

 

 

(269,401

)

 

 

8.08

 

Forfeited or expired

 

 

(19,816

)

 

 

7.27

 

Balance, December 31, 2015

 

 

640,759

 

 

$

4.92

 

 

As of December 31, 2015, we had approximately $2.0 million in total unrecognized compensation expense related to our restricted stock unit awards which is to be recognized over a weighted-average period of approximately 2.2 years.

[e] Stock Warrants

The following is a summary of outstanding warrants to purchase common stock at December 31, 2015:

 

 

 

Total

 

 

 

 

 

 

 

 

 

Outstanding

 

 

Exercise

 

 

 

 

 

and

 

 

price per

 

 

 

 

 

Exercisable

 

 

Share

 

 

Expiration Date

(1) Series A Warrants issued in July 2014 financing

 

 

2,779,933

 

 

 

4.00

 

 

July 2019

(2) Series B Warrants issued in July 2014 financing

 

 

670,269

 

 

 

4.00

 

 

July 2019

(3) Series A-1 Warrants issued in April 2015 financing

 

 

239,234

 

 

 

2.40

 

 

October 2020

 

No warrants were exercised for the year ended December 31, 2015. For the year ended December 31, 2014, all the Pre-Funded Series B warrants were exercised at a per unit price of $0.01, a total of 1,340,538 shares of common stock were issued for proceeds of $13,405. No Series A and Series B warrants from the July 2014 financing were exercised in 2014.

The Series A and Series B warrants issued in the July 2014 financing are classified as liabilities. The estimated fair value of warrants issued and classified as liabilities is reassessed at each reporting date using the Black-Scholes option pricing model. The Series A-1 Warrants issued in the April 2015 financing are classified as equity and are not reassessed for their fair value at the end of each reporting date. The following assumptions were used to value the warrants that are classified as liabilities on the following reporting dates:

  

 

 

As of

 

 

 

December 31,

 

Series A and Series B Warrant Valuation Assumptions

 

2015

 

 

2014

 

Risk-free interest rates

 

 

1.42

%

 

 

1.51

%

Expected dividend yield

 

 

0

%

 

 

0

%

Expected life

 

3.50 years

 

 

4.50 years

 

Expected volatility

 

 

77

%

 

 

63

%

 

[f] Shareholder Rights Plan

We have a Shareholder Rights Plan which was adopted in July 1996 and subsequently amended in July 2002, October 2005, August 2006, and May 2008 (the “Rights Plan”). Under the Plan our Board of Directors declared a dividend of one Preferred Stock Purchase Right (Right) for each outstanding common share of OncoGenex. Subject to the Rights Plan, each Right entitles the registered holder to purchase from us one one-hundredth of a share of Series A Junior Participating Preferred Stock at an exercise price of $140, subject to adjustment. These Rights provide the holders with the right to purchase, in the event a person or group acquires 15% or more of our common stock, additional shares of our common stock having a market value equal to two times the exercise price of the Right. Pursuant to the Rights Plan, the one-for-eighteen reverse stock split caused a proportionate adjustment of the number of Rights associated with each share of common stock. Currently, eighteen Rights are associated with each share of common stock.

[g] 401(k) Plan

We maintain a 401(k) plan. Following the Arrangement, the Board of Directors of OncoGenex amended and restated the 401(k) plan whereas our securities are no longer offered as an investment option. This amendment prohibits the inclusion of our shares in the 401(k) plan, as well as any match of our shares to employee contributions.

[h] Loss per common share

The following table presents the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share and share amounts):

 

 

 

Years ended December 31,

 

 

 

2015

 

 

2014

 

 

2013

 

Numerator

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(16,801

)

 

$

(26,240

)

 

$

(31,849

)

Denominator

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding

 

 

26,147,344

 

 

 

18,098,799

 

 

 

14,683,389

 

Basic and diluted net loss per common share

 

$

(0.64

)

 

$

(1.45

)

 

$

(2.17

)

 

As of December 31, 2015, 2014 and 2013 a total of 5.8 million, 7.0 million and 3.0 million options, restricted stock units and warrants, respectively, have not been included in the calculation of potential common shares as their effect on diluted per share amounts would have been anti-dilutive.